Synthesis and evaluation of oligo-1,3-thiazolecarboxamide derivatives as HIV-1 reverse transcriptase inhibitors. 2000

V A Ryabinin, and O D Zakharova, and E Y Yurchenko, and O A Timofeeva, and I V Martyanov, and A A Tokarev, and E F Belanov, and N I Bormotov, and L Tarrago-Litvak, and M L Andreola, and S Litvak, and G A Nevinsky, and A N Sinyakov
Institute of Molcular Biology, Koltsoro, Novosibirsk Region, Russia.

A set of oligo-1,3-thiazolecarboxamide derivatives able to interact with the minor groove of nucleic acids was synthesized. These oligopeptides contained different numbers of thiazole units presenting dimethylaminopropyl or EDTA moieties on the C-terminus, and aminohexanoyl or EDTA moieties on the N-terminus. The inhibition of such compounds on HIV-1 reverse transcriptase activity was evaluated using different model template primer duplexes: DNA x DNA, RNA x DNA, DNA x RNA and RNA x RNA. The biological properties of the thiazolecarboxamide derivatives were compared to those of distamycin, another minor groove binder which contains three pyrrole rings. Similar to distamycin, the thiazole containing oligopeptides were good inhibitors of the reverse transcription reaction in the presence of DNA x DNA. But in contrast to distamycin, the oligothiazolide derivatives were able to inhibit reverse transcription in the presence of RNA x DNA or DNA x RNA template primers. Both distamycin and oligothiazolecarboxamides had low affinity for RNA x RNA duplexes. The inhibition obtained with the newly synthesized thiazolecarboxamides showed that these compounds were more powerful and versatile inhibitors of the RT-dependent polymerization than the natural minor groove binder distamycin.

UI MeSH Term Description Entries
D009682 Magnetic Resonance Spectroscopy Spectroscopic method of measuring the magnetic moment of elementary particles such as atomic nuclei, protons or electrons. It is employed in clinical applications such as NMR Tomography (MAGNETIC RESONANCE IMAGING). In Vivo NMR Spectroscopy,MR Spectroscopy,Magnetic Resonance,NMR Spectroscopy,NMR Spectroscopy, In Vivo,Nuclear Magnetic Resonance,Spectroscopy, Magnetic Resonance,Spectroscopy, NMR,Spectroscopy, Nuclear Magnetic Resonance,Magnetic Resonance Spectroscopies,Magnetic Resonance, Nuclear,NMR Spectroscopies,Resonance Spectroscopy, Magnetic,Resonance, Magnetic,Resonance, Nuclear Magnetic,Spectroscopies, NMR,Spectroscopy, MR
D009842 Oligopeptides Peptides composed of between two and twelve amino acids. Oligopeptide
D013844 Thiazoles Heterocyclic compounds where the ring system is composed of three CARBON atoms, a SULFUR and NITROGEN atoms. Thiazole
D054303 HIV Reverse Transcriptase A reverse transcriptase encoded by the POL GENE of HIV. It is a heterodimer of 66 kDa and 51 kDa subunits that are derived from a common precursor protein. The heterodimer also includes an RNAse H activity (RIBONUCLEASE H, HUMAN IMMUNODEFICIENCY VIRUS) that plays an essential role the viral replication process. Reverse Transcriptase, HIV,Reverse Transcriptase, Human Immunodeficiency Virus,Transcriptase, HIV Reverse
D018894 Reverse Transcriptase Inhibitors Inhibitors of reverse transcriptase (RNA-DIRECTED DNA POLYMERASE), an enzyme that synthesizes DNA on an RNA template. Reverse Transcriptase Inhibitor,Inhibitors, Reverse Transcriptase,Inhibitor, Reverse Transcriptase,Transcriptase Inhibitor, Reverse
D019380 Anti-HIV Agents Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS. AIDS Drug,AIDS Drugs,Anti-AIDS Agents,Anti-AIDS Drug,Anti-HIV Agent,Anti-HIV Drug,Anti-AIDS Drugs,Anti-HIV Drugs,Agent, Anti-HIV,Agents, Anti-AIDS,Agents, Anti-HIV,Anti AIDS Agents,Anti AIDS Drug,Anti AIDS Drugs,Anti HIV Agent,Anti HIV Agents,Anti HIV Drug,Anti HIV Drugs,Drug, AIDS,Drug, Anti-AIDS,Drug, Anti-HIV,Drugs, AIDS,Drugs, Anti-AIDS,Drugs, Anti-HIV

Related Publications

V A Ryabinin, and O D Zakharova, and E Y Yurchenko, and O A Timofeeva, and I V Martyanov, and A A Tokarev, and E F Belanov, and N I Bormotov, and L Tarrago-Litvak, and M L Andreola, and S Litvak, and G A Nevinsky, and A N Sinyakov
August 2014, ChemMedChem,
V A Ryabinin, and O D Zakharova, and E Y Yurchenko, and O A Timofeeva, and I V Martyanov, and A A Tokarev, and E F Belanov, and N I Bormotov, and L Tarrago-Litvak, and M L Andreola, and S Litvak, and G A Nevinsky, and A N Sinyakov
August 2000, Bioorganic & medicinal chemistry letters,
V A Ryabinin, and O D Zakharova, and E Y Yurchenko, and O A Timofeeva, and I V Martyanov, and A A Tokarev, and E F Belanov, and N I Bormotov, and L Tarrago-Litvak, and M L Andreola, and S Litvak, and G A Nevinsky, and A N Sinyakov
August 2013, Organic and medicinal chemistry letters,
V A Ryabinin, and O D Zakharova, and E Y Yurchenko, and O A Timofeeva, and I V Martyanov, and A A Tokarev, and E F Belanov, and N I Bormotov, and L Tarrago-Litvak, and M L Andreola, and S Litvak, and G A Nevinsky, and A N Sinyakov
August 2011, Bioorganic & medicinal chemistry,
V A Ryabinin, and O D Zakharova, and E Y Yurchenko, and O A Timofeeva, and I V Martyanov, and A A Tokarev, and E F Belanov, and N I Bormotov, and L Tarrago-Litvak, and M L Andreola, and S Litvak, and G A Nevinsky, and A N Sinyakov
July 2001, Bioorganic & medicinal chemistry letters,
V A Ryabinin, and O D Zakharova, and E Y Yurchenko, and O A Timofeeva, and I V Martyanov, and A A Tokarev, and E F Belanov, and N I Bormotov, and L Tarrago-Litvak, and M L Andreola, and S Litvak, and G A Nevinsky, and A N Sinyakov
April 1997, Drug design and discovery,
V A Ryabinin, and O D Zakharova, and E Y Yurchenko, and O A Timofeeva, and I V Martyanov, and A A Tokarev, and E F Belanov, and N I Bormotov, and L Tarrago-Litvak, and M L Andreola, and S Litvak, and G A Nevinsky, and A N Sinyakov
April 2013, Bioorganic & medicinal chemistry,
V A Ryabinin, and O D Zakharova, and E Y Yurchenko, and O A Timofeeva, and I V Martyanov, and A A Tokarev, and E F Belanov, and N I Bormotov, and L Tarrago-Litvak, and M L Andreola, and S Litvak, and G A Nevinsky, and A N Sinyakov
December 2013, Organic and medicinal chemistry letters,
V A Ryabinin, and O D Zakharova, and E Y Yurchenko, and O A Timofeeva, and I V Martyanov, and A A Tokarev, and E F Belanov, and N I Bormotov, and L Tarrago-Litvak, and M L Andreola, and S Litvak, and G A Nevinsky, and A N Sinyakov
May 2012, European journal of medicinal chemistry,
V A Ryabinin, and O D Zakharova, and E Y Yurchenko, and O A Timofeeva, and I V Martyanov, and A A Tokarev, and E F Belanov, and N I Bormotov, and L Tarrago-Litvak, and M L Andreola, and S Litvak, and G A Nevinsky, and A N Sinyakov
November 2009, Yao xue xue bao = Acta pharmaceutica Sinica,
Copied contents to your clipboard!